After a six-month run-in period , we randomly assigned 1277 subjects ( mean age , 52 years ; mean forced expiratory volume in one second [ FEV1 ] , 77 percent of the predicted value ; 73 percent men ) to twice-daily treatment with 400 microg of budesonide or placebo , inhaled from a dry-powder inhaler , for three years .
